Protagenic Therapeutics (PTIX) CFO Alexander Arrow set to exit role
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Protagenic Therapeutics, Inc. reported a leadership change in its finance function. On March 31, 2026, the Board of Directors notified Chief Financial Officer Alexander Arrow, MD that his employment with the company will be terminated, effective April 30, 2026. This change affects the company’s senior management team but the filing does not describe any replacement plan or additional terms.
Positive
- None.
Negative
- Chief Financial Officer termination: On March 31, 2026, the Board notified CFO Alexander Arrow, MD that his employment will be terminated effective April 30, 2026, creating a near-term transition in the company’s financial leadership.
Insights
Protagenic’s CFO is scheduled to depart at the end of April 2026.
The company states that on March 31, 2026 its Board notified Chief Financial Officer Alexander Arrow, MD that his employment will be terminated effective April 30, 2026. This represents a change in leadership over financial reporting and capital planning.
Departures from the CFO role can raise questions about continuity in financial oversight and internal control processes, especially for smaller or emerging growth companies. The filing does not describe reasons for the termination or announce a successor, so future disclosures will be needed to understand the longer-term finance leadership structure.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board notice date: March 31, 2026
CFO termination effective date: April 30, 2026
Company address ZIP code: 10010
+1 more
4 metrics
Board notice date
March 31, 2026
Date Board notified CFO of termination
CFO termination effective date
April 30, 2026
Effective date for Chief Financial Officer’s employment termination
Company address ZIP code
10010
ZIP code for principal executive offices in New York, NY
Company phone number
212-994-8200
Telephone number for Protagenic Therapeutics, Inc.
Key Terms
Emerging growth company, Item 5.02, principal executive offices, OTC Markets
4 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02. Departure of Directors or Certain Officers;"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 5.02 regulatory
"Item 5.02. Departure of Directors or Certain Officers; Election of Directors;"
principal executive offices financial
"149 Fifth Avenue , Suite 500 , New York , NY | | 10010 (Address of principal executive offices)"
OTC Markets market
"Protagenic Therapeutics, Inc. Common Stock | | PTIX | | OTC Markets"
Over-the-counter (OTC) markets are trading venues where buyers and sellers deal directly through dealers or electronic networks instead of on a formal exchange; think of a neighborhood flea market versus a supermarket. They matter to investors because OTC-listed stocks often represent smaller or international companies with fewer reporting requirements, which can mean lower liquidity, wider price swings and higher risk but sometimes earlier access to growth opportunities.
FAQ
What leadership change did Protagenic Therapeutics (PTIX) disclose in this 8-K?
Protagenic Therapeutics disclosed that its Chief Financial Officer, Alexander Arrow, MD, will have his employment terminated. The Board notified him on March 31, 2026, and the termination is effective April 30, 2026, altering the company’s senior finance leadership.
When is the Protagenic Therapeutics CFO termination effective?
The CFO termination is effective on April 30, 2026. The company’s Board notified Chief Financial Officer Alexander Arrow, MD on March 31, 2026, providing one month between notice and effective date for transition and handover of responsibilities.
Which Protagenic Therapeutics executive is affected by this 8-K filing?
The filing concerns Alexander Arrow, MD, the Chief Financial Officer of Protagenic Therapeutics. The Board informed him that his employment will be terminated effective April 30, 2026, signaling a change in the company’s top financial management role.
Does Protagenic Therapeutics state why the CFO is being terminated?
The company does not state a reason for the CFO’s termination in this disclosure. It only reports that the Board notified Chief Financial Officer Alexander Arrow, MD on March 31, 2026, that his employment will end effective April 30, 2026.
Is a successor CFO named in the Protagenic Therapeutics 8-K?
No successor CFO is named in this disclosure. The company only reports that Chief Financial Officer Alexander Arrow, MD was notified of termination effective April 30, 2026, without mentioning an interim or permanent replacement for the finance leadership role.